TTP and OS to the ≥2nd line cetuximab-containing treatment according to KRAS, BRAF, PIK3CA mutations status, PTEN protein expression, AREG and EREG mRNA expression and grade of skin rash in the KRAS WT patients′ population. The gene discussed is BRAF; the disease is neoplasm.